|1.||Singh, Rakesh K: 3 articles (08/2012 - 11/2007)|
|2.||Brard, Laurent: 3 articles (08/2012 - 11/2007)|
|3.||Kim, Kyukwang: 2 articles (08/2012 - 11/2007)|
|4.||Lange, Thilo S: 2 articles (05/2008 - 11/2007)|
|5.||Horan, Timothy C: 1 article (08/2012)|
|6.||Moore, Richard G: 1 article (08/2012)|
|7.||Kristjansdottir, Katrin: 1 article (08/2012)|
|8.||Choi, Joong Sub: 1 article (08/2012)|
|9.||Shaw, Sunil K: 1 article (05/2008)|
|10.||Kim, Kyu Kwang: 1 article (05/2008)|
|1.||Endometrial Neoplasms (Endometrial Cancer)
08/01/2012 - "7Me-IEITC demonstrated promising cytotoxic effects in endometrial cancer cell line model."
08/01/2012 - "7Me-IEITC treatment caused mitochondrial transmembrane potential reduction, elevated the production of ROS, leading to activation of apoptosis in endometrial cancer KLE and ECC-1 cells. "
08/01/2012 - "The cell viability of 7Me-IEITC treated ECC-1 and KLE endometrial cancer cell was determined by MTS assay. "
|2.||Prostatic Neoplasms (Prostate Cancer)
|3.||Ovarian Neoplasms (Ovarian Cancer)
05/01/2008 - "7Me-IEITC is a potent and growth-suppressing agent to cell lines derived from ovarian cancers by causing deactivation of survival signals, apoptosis, and cell-cycle arrest."
05/01/2008 - "The viability of ovarian cancer cell lines (SKOV-3, OVCAR-3) in comparison to pancreatic and prostate cancer cell lines, primary fibroblast and immortalized trophoblasts after treatment with 7Me-IEITC was analyzed. "